Aventis To Continue Cariporide Development In Coronary Artery Bypass
Executive Summary
Aventis Pharma will focus its late-stage cariporide development efforts on treating patients undergoing coronary artery bypass grafting, instead of the original indication for acute coronary syndrome, Hoechst Marion Roussel reported in a July 22 announcement on priority pipeline candidates for the merged HMR/Rhone-Poulenc Rorer.